Hans Biomed한스바이오메드
042520 · KOSDAQ · ₩042520 · 한스바이오메드
₩17,030▼ ₩500 (2.85%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩90B | ₩81B | ₩78B | ₩74B | ₩59B |
| Cost of sales | ₩38B | ₩29B | ₩33B | ₩29B | ₩30B |
| Gross profit | ₩52B | ₩52B | ₩45B | ₩46B | ₩29B |
| Operating income | −₩26B | ₩626M | −₩4.2B | ₩1.3B | −₩20B |
| Net income | −₩32B | −₩7.8B | −₩24B | ₩4.9B | −₩22B |
| Net income to shareholders | −₩31B | −₩7.2B | −₩23B | ₩6.1B | −₩18B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩126B | ₩122B | ₩122B | ₩132B | ₩129B |
| Current assets | ₩56B | ₩50B | ₩50B | ₩54B | ₩51B |
| Cash and equivalents | ₩8.1B | ₩7.3B | ₩6.1B | ₩7.5B | ₩7.1B |
| Total liabilities | ₩93B | ₩55B | ₩72B | ₩84B | ₩82B |
| Current liabilities | ₩81B | ₩50B | ₩65B | ₩74B | ₩61B |
| Borrowings | ₩41B | ₩37B | ₩39B | ₩54B | ₩49B |
| Total equity | ₩34B | ₩67B | ₩50B | ₩47B | ₩48B |
| Shareholders' equity | ₩34B | ₩67B | ₩49B | ₩46B | ₩44B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩318M | ₩1.8B | −₩3.7B | −₩4.3B | −₩15B |
| Capital spending | ₩1.7B | ₩2.6B | ₩1.9B | ₩4B | ₩4.9B |
| Free cash flow | −₩1.4B | −₩836M | −₩5.7B | −₩8.3B | −₩20B |
Consolidated where available. Amounts in won.
Also known as: Hans Biomed / 한스바이오메드 / 042520 / KRX:042520
Source: KRX statistical information